Cidara’s development pipeline comprises new approaches aimed at transforming existing treatment and prevention paradigms, leveraging drug-Fc conjugates (DFCs) from its proprietary Cloudbreak® platform that target influenza, cancers and other serious diseases.
Pipeline
Preclinical
IND-Enabling
Phase 1
Phase 2
Phase 3
CD388
Targets Viral Neuraminidase
Seasonal Influenza
CBO421
Targets CD73
Solid Tumors
Undisclosed
Targets CD73/PD-1
Solid Tumors
Undisclosed
Targets CCR5
Solid Tumors
